Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster II
Session Type: Poster Session (Monday)
Session Time: 9:00AM-11:00AM
Three randomized controlled trials in systemic sclerosis (SSc) demonstrated that autologous hematopoietic stem cell transplantation (aHSCT) is superior to standard cyclophosphamide therapy. This EBMT trial was a multi-center, prospective non-interventional study (NISCC1), designed to further decipher aHSCT efficacy and safety in real-life practice and to search for prognostic factors.
Methods: All consecutive adult patients, fulfilling the 2013 ACR/EULAR classification criteria for SSc, and undergoing a first aHSCT between December 2012 and February 2016 were included in the study. Primary endpoint was progression free survival (PFS) after two years. Secondary endpoints were overall survival (OS), non-relapse mortality (NRM) and response (RESP) to treatment, defined as >25% improvement in modified Rodnan skin score (mRSS) and/or ≥10% improvement in lung function test for Forced vital capacity (FVC) or diffusion capacity for carbon monoxide (DLCO) and with no need for further immunosuppression.
Results: Eighty SSc patients were included. Median follow-up was 24 (6-57) months after aHSCT using cyclophosphamide plus antithymocyte globulin conditioning for all, with CD34+ selection in 35 (44%) patients. Following aHSCT, G-CSF was administered to 34 (43%) patients for a median duration of five (1-13) days. Median time following aHSCT to neutrophil engraftment was 11 (8-24) days and nine (1-25) days to platelet engraftment. There was an inverse correlation between the number of CD34+ cells infused and the time to engraftment (Spearman: r2= -0.31; p< .01), while the number of infused CD34+ cells or addition of G-CSF until aplasia recovery were not associated with a reduced number of infectious complications (p=0.32). At two years, PFS was 81.8%, OS was 90% and RESP was 88.7%. The 100 day NRM was 6.25% (n=5) with four deaths from cardiac events. Mean mRSS decreased from 23.9 at baseline to 14.2 at month 12 and 12.6 at month 24 (n=55, p< 0.001). Regarding lung function, mean FVC increased from 73.6% at baseline to 79.5% at month 12, and 80.6% at month 24 (n=37, p< 0.001); mean DLCO was 60.2% at baseline, 59.7% at month 12 and 60.4% at month 24 (n=35). By multivariate analysis, baseline mRSS >24 and older age at transplant were associated with lower PFS. CD34+-selection was associated with better RESP.
Conclusion: The NISCC1 study is the largest prospective cohort today demonstrating the efficacy and safety of aHSCT in eighty severe SSc patients in a real-life setting. NISCC1 showed superior response in patients with CD34+ graft selection with regard to response to treatment no increase in the rate of infectious complications.
To cite this abstract in AMA style:Henes J, Oliveira M, Labopin M, Badoglio M, Scherer H, Del Papa N, Daikeler T, Schmalzing M, Schroers R, Martin T, Pugnet G, Simoes B, Michonneau D, Marijt E, Lioure B, Bay J, Snowden J, Rovira M, Huynh A, Onida F, Kanz L, Marjanovic Z, Farge D. Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/baseline-skin-score-older-age-and-cd34-selection-influence-the-outcome-of-autologous-stem-cell-transplantation-for-systemic-sclerosis-results-of-a-prospective-non-interventional-study-from/. Accessed April 13, 2021.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-skin-score-older-age-and-cd34-selection-influence-the-outcome-of-autologous-stem-cell-transplantation-for-systemic-sclerosis-results-of-a-prospective-non-interventional-study-from/